In melanoma, its inhibition was associated with enhanced immune infiltration and improved response to PD-1 blockade in preclinical models, whereas in bladder cancer, high SEPHS1 expression may be associated with a more immunogenic phenotype and improved response to checkpoint blockade. This evidence concerns the gene PDCD1 and urinary bladder carcinoma.